EGFR-TKIゲフィチニブの後発医薬品(Gefitinib Mylan)について、EMAが局所進行または転移性のEGFR遺伝子変異陽性非小細胞肺がんに対する適応承認を支持【ESMO】

EMA Recommends Granting a Marketing Authorisation for Generic Gefitinib

Gefitinib Mylan is intended for the treatment of patients with locally advanced or metastatic NSCLC with activating mutations of EGFR

 

 

コメント

Leave a comment

Your email address will not be published.


*